On May 2, 2024, Ora, Inc., a global leader in ophthalmic contract research, announced an exclusive partnership with the Singapore Eye Research Institute (SERI), a renowned organization for pioneering eye research and preclinical studies.
By leveraging SERI’s expertise in non-clinical ophthalmic animal studies and Ora’s commitment to top-tier research, the collaboration seeks to provide comprehensive research support to early-stage innovators worldwide.
SERI, known for its commitment to scientific rigor and ethical preclinical operations, is set to partner closely with Ora’s biopharmaceutical and device clients. With a focus on evaluating therapeutic candidates across a range of ocular-specific therapeutic areas, the collaboration aims to accelerate the development of innovative treatments for various eye disorders.
A rewarding alliance
Key benefits of this partnership include a comprehensive suite of preclinical services, boasting state-of-the-art resources and expertise to ensure precision and thoroughness in every evaluation.
Additionally, SERI boasts an unparalleled array of non-GLP systemic safety, toxicity and efficacy models, spanning both anterior and posterior segments of the eye. This diversity allows for tailored solutions for each research endeavor, enhancing the accuracy and relevance of preclinical studies.
Furthermore, Ora’s partnership with SERI is expected to significantly reduce timelines for evaluating potential therapeutic candidates, allowing researchers to streamline the development process and accelerate the delivery of new treatments to market.
Quality assurance is a cornerstone of this collaboration. SERI’s AALAC accreditation ensures reliability and reproducibility in preclinical operations and provides clients with confidence in the integrity of the research conducted.
The partnership also serves as a catalyst for Ora’s expansion of research offerings, granting clients access to an even broader range of services and expertise. This expanded capacity opens new avenues for innovation and discovery in the field of ophthalmology, promising exciting advancements in the years to come.
About Ora
Ora is the world’s leading full-service ophthalmic drug and device development firm, supporting organizations from concept to market with refined methodologies and global regulatory strategies. With over 45 years of experience, Ora has helped clients earn more than 85 product approvals, leveraging the expertise of its extensive team of ophthalmic experts and R&D professionals.
About SERI
SERI is Singapore’s premier national research institute for ophthalmic and vision research, renowned for its multidisciplinary approach and breakthroughs in understanding and treating eye diseases. With a focus on basic, clinical, and translational research, SERI collaborates with global institutions to advance eye care and enhance patient outcomes.
Editor’s Note: For more information, check out the official press release in here.